发明授权
US06207815B1 Family of high affinity, modified antibodies for cancer treatment
失效
高亲和力家族，用于癌症治疗的修饰抗体
- 专利标题： Family of high affinity, modified antibodies for cancer treatment
- 专利标题（中）： 高亲和力家族，用于癌症治疗的修饰抗体
-
申请号： US08479285申请日： 1995-06-07
-
公开(公告)号： US06207815B1公开(公告)日： 2001-03-27
- 发明人: Peter S. Mezes , Brian B. Gourlie , Mark W. Rixon , Jeffrey Schlom , Donald A. Kaplan , W. H. Kerr Anderson
- 申请人： Peter S. Mezes , Brian B. Gourlie , Mark W. Rixon , Jeffrey Schlom , Donald A. Kaplan , W. H. Kerr Anderson
- 主分类号： C12N1514
- IPC分类号： C12N1514
摘要：
This invention concerns a family of chimeric antibodies with high affinities to a high molecular weight, tumor-associated sialylated glycoprotein antigen (TAG-72) of human origin. These antibodies have (1) high affinity animal VH and VL sequences which mediate TAG-72 binding and (2) human CH and CL regions. They are thought to produce significantly fewer side-effects when administered to human patients by virtue of their human CH and CL antibody domains. The nucleotide and amino acid sequences of VH&agr;TAG VH, CC46 VH, CC49H, CC83 VH, and CC92 VH, and CC49L, CC83 VL, and CC92 VL idiotype sequences are disclosed, as well as in vivo methods of treatment and diagnostic assay using these chimeric antibodies.